RecruitingPhase 2Phase 3NCT06477536
Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Enrollment
33 participants
Start Date
Sep 2, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria4
- Patients participated in the preceding placebo-controlled Phase 2 study （HB0034-04）and completed at least the Week 12 visit of the HB0034-04 study
- Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment
- Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug;
- Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules
Exclusion Criteria1
- Patients who are experiencing GPP flare
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGHB0034
300mg, i.v. Q4W
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06477536